HUTCHMED (NASDAQ:HCM) Shares Gap Down – Time to Sell?

HUTCHMED (China) Limited (NASDAQ:HCM)’s share price gapped down prior to trading on Wednesday . The stock had previously closed at $15.01, but opened at $14.07. HUTCHMED shares last traded at $13.93, with a volume of 34,031 shares trading hands.

Analyst Ratings Changes

Separately, StockNews.com cut shares of HUTCHMED from a “buy” rating to a “hold” rating in a research note on Monday, November 18th.

HUTCHMED Trading Down 7.6 %

The firm’s fifty day moving average price is $16.15 and its 200 day moving average price is $17.74. The company has a quick ratio of 2.68, a current ratio of 2.81 and a debt-to-equity ratio of 0.07.

Hedge Funds Weigh In On HUTCHMED

Large investors have recently made changes to their positions in the stock. Public Employees Retirement System of Ohio acquired a new position in shares of HUTCHMED in the 3rd quarter worth approximately $35,000. Blue Trust Inc. lifted its holdings in shares of HUTCHMED by 638.2% in the 3rd quarter. Blue Trust Inc. now owns 3,536 shares of the company’s stock worth $69,000 after acquiring an additional 3,057 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in HUTCHMED by 63.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,966 shares of the company’s stock worth $117,000 after buying an additional 2,321 shares in the last quarter. Rhumbline Advisers lifted its holdings in HUTCHMED by 8.1% during the 2nd quarter. Rhumbline Advisers now owns 7,553 shares of the company’s stock worth $129,000 after buying an additional 564 shares in the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new stake in HUTCHMED during the 2nd quarter worth approximately $213,000. 8.82% of the stock is currently owned by institutional investors and hedge funds.

HUTCHMED Company Profile

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.